EGFR突变并非肺腺癌根治切除患者中枢神经系统转移的预后因素

29 March 2022

EGFR mutation is not a prognostic factor for CNS metastasis in curatively resected lung adenocarcinoma patients

（LUNG CANCER；IF:5.602）

• Xianping Liu, Xiao Li, Chao Zhang, Jian Jin, Zhenfan Wang, Rongxin Xiao, Kunkun Sun, Jun Wang, Wenzhao Zhong, Fan Yang.EGFR mutation is not a prognostic factor for CNS metastasis in curatively resected lung adenocarcinoma patients. Lung Cancer. 2022.

• CORRESPONDENCE TO : yangfan@pkuph.edu.cn

Introduction 引言

For NSCLC patients with complete resection, the prognostic role of EGFR mutation for recurrence, especially for CNS metastasis, is still controversial. In this study, we aimed to identify the characteristics of the recurrence pattern of lung adenocarcinoma based on EGFR mutation status.

对于完全切除的非小细胞肺癌（NSCLC）患者，EGFR 突变对复发尤其是中枢神经系统（CNS）转移的预后判断价值仍存在争议。在本次研究中，我们旨在根据 EGFR 突变情况确定肺腺癌复发模式的特征。

Methods 方法

Overall, 888 patients with completely surgically resected LUAD who underwent EGFR mutation status analysis from two Chinese institutions were included. Sites and data of initial recurrence were recorded. The recurrence patterns according to EGFR mutation status were estimated by Kaplan-Meier analysis, and hazard rate curves were generated.

共纳入了来自中国两家机构的888例完全手术切除的肺腺癌患者，这些患者全部接受了EGFR突变状态分析。记录最初复发的部位和数据。通过 Kaplan-Meier 分析估计根据 EGFR 突变状态的复发模式，并生成风险比曲线。

Results 结果

245 (27.6%) of 888 patients suffered from recurrence. Before and after PSM, there were no statistically significant differences between the EGFR mutation and EGFR WT groups for all types of recurrence, including CNS metastasis. Multivariable Cox analysis revealed that EGFR status was not a risk factor for all types of recurrence, including CNS metastasis (HR 0.88, 95% CI 0.54-1.46, p=0.632). The CNS metastasis hazard curve in the EGFR mutation group showed that the first peak occurred at approximately 24-26 months after surgery, which was 10 months later than that in the EGFR WT group. In addition, the second peak time in the EGFR mutation group was approximately 2 years later than that in the EGFR WT group.

888例患者中有245例（27.6%）出现复发。在倾向性匹配分析（PSM）之前和之后，EGFR 突变组和 EGFR 野生型组对于所有类型的复发（包括 CNS 转移）没有统计学上的显著差异。多变量 Cox 分析显示，EGFR突变情况并不是所有复发类型的危险因素，包括CNS转移（HR 0.88, 95% CI 0.54-1.46, p=0.632）。EGFR突变组CNS转移风险曲线显示，第一个高峰出现在术后约24-26个月，比EGFR野生型组晚10个月。此外，EGFR突变组的第二个峰值时间比EGFR野生型组晚约2年。

Conclusions 结论

EGFR mutation was not an independent prognostic factor for postoperative recurrence. EGFR-mutated LUADs did not have a clinical course with a higher incidence of CNS metastasis. However, the peak hazards for recurrence of CNS metastasis occur at a later time point in the EGFR mutant group compared with the EGFR wild type group.

EGFR突变不是术后复发的独立预后因素。EGFR 突变的肺腺癌没有更高CNS转移风险的临床特点。然而，与EGFR野生型组相比，EGFR突变组中CNS转移复发风险的峰值发生在较晚的时间点。

喜欢SCI天天读的理由

陪您一起学习SCI医学论文

每天5分钟，让自己的英语牛逼起来

特殊福利让您惊喜连连

复制链接或点击原文链接，即可下载SCI原文  

W116N05

链接：https://pan.baidu.com/s/1oirEpImCra-K0aAHkt2xeg

提取码：0t5z